San Antonio Claude D. Pepper Older Americans Independence Center
圣安东尼奥克劳德·D·佩珀美国老年人独立中心
基本信息
- 批准号:10455762
- 负责人:
- 金额:$ 126.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-06-15 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:AgingAlzheimer&aposs disease pathologyAmericanAwarenessBehavior TherapyBiology of AgingBiometryCallithrixCapsicumCell AgingChronic DiseaseClinicalClinical PharmacologyClinical ResearchClinical TrialsClinical Trials DesignCognitiveCommunitiesCustomDevelopmentDiamondDiseaseEducationElderlyEpigenetic ProcessExerciseFoundationsFundingGDF8 geneGerontologyGeroscienceGoalsGrantHumanImmuneInflammationInformaticsInfrastructureInstitutesInstitutionInterventionK-Series Research Career ProgramsKnowledgeLaboratoriesLeadershipLongevityMaintenanceMediator of activation proteinMedication ManagementMetabolic dysfunctionMetforminMethylene blueMitochondriaModelingMonkeysOxytocinPatientsPharmacologyPhasePilot ProjectsPlayPrincipal InvestigatorProcessResearchResearch DesignResearch PersonnelResearch SupportResourcesScientistSeriesServicesShockSirolimusSiteTestingTrainingTranslatingbasebench to bedsideclinical centercohesiondata managementdisabilitydrug developmentdysbiosiseducation researchexhaustionfirst-in-humanfrailtygut microbiomehealthspanhealthy aginghuman diseaseimprovedinnovationknowledge baselifestyle interventionmTOR Inhibitormeetingsmicrobiomemild cognitive impairmentmultidisciplinarynonhuman primatenutritionoperationoral microbiomepre-clinical researchprogramsrecruitsarcopeniasquare footstem cellsstress reductionsymposiumtrial designweb site
项目摘要
A core tenet of the geroscience concept is that multiple human diseases arise from aging itself. Thus, the
central theme of the San Antonio (SA) Claude D. Pepper Older Americans Independence Center (OAIC)
is translational geroscience – moving research on the basic biology of aging from the laboratory bench to the
clinic, with the overarching goal of promoting healthy aging and developing desperately needed treatments,
mainly pharmacological, for aging-related diseases. This goal is achieved through the following Aims:
1) Expand the knowledge base in translational geroscience by catalyzing transformative research; 2) Create
a cadre of multidisciplinary early-stage investigators with customized expertise in translational geroscience; 3)
Serve as a resource and partner to investigators from other OAICs and institutions; and 4) Provide intellectual
leadership, disseminate knowledge, and stimulate discussion on translational geroscience-related themes.
The SA OAIC achieves these Aims through a Leadership and Administrative Core (LAC) that directs
operations and sponsors several enrichment and dissemination activities; a Pilot and Exploratory Studies Core
(PESC) that provides merit-based support for rigorously designed studies; a Research Education Component
(REC) that expands a greatly needed cadre of uniquely qualified scientists cross-trained in aging biology and
translational geroscience; a Pre-Clinical Research Core (RC1) which supports research in marmoset monkeys;
a Clinical Research and Pharmacology Core (RC2) that delivers comprehensive trial support for
recruitment/retention, assessments, pharmacology, and data management; and a Trial Design and Integrative
Informatics Core (RC3) that provides comprehensive study design, biostatistics and informatics services.
During the ~4 years since its funding, the SA OAIC supported 46 PIs, performing transformative translational
geroscience-focused research in essentially all pillars/hallmarks of aging. For example, RC1 is conducting the
only known lifespan and healthspan study on mTOR inhibitors in nonhuman primates. RC2 and RC3 carried out
the first trial on rapamycin to examine immune and cognitive effects in healthy older adults and performed the
first-in-man studies on senolytics. The OAIC supported 10 Scholars who are making transformative discoveries
(e.g. first demonstration of cellular senescence as a key mediator of Alzheimer's pathology) and receiving highly
competitive career development awards from the NIA/AFAR (Beeson, Irene Diamond) and the VA.
The SA OAIC is built on a unique foundation provided by UTHSCSA's exceptional and tightly integrated
resources: a Nathan Shock Center, a site of the Interventions Testing Program (ITP), a GRECC, a T32 Training
Grant on Geroscience, and a robust Barshop Institute that unites aging research at UTHSCSA. We are the only
OAIC with all of these synergistic components available. In addition, the SA OAIC receives unparalleled
institutional commitment (~$600,000/year), including a new ~$100M 109,000 sq. ft. building – specific for the
Barshop Institute – that will house the OAIC, Shock Center, and the ITP in a centrally located facility.
老年学概念的一个核心原则是,人类的多种疾病是由衰老本身引起的。因此,
圣安东尼奥(SA)克劳德·D·佩珀老年美国人独立中心(OAIC)的中心主题
翻译老年学--将衰老基础生物学的研究从实验室转移到
诊所的首要目标是促进健康老龄化和开发急需的治疗方法,
主要是药理作用,用于衰老相关疾病。这一目标是通过以下目标实现的:
1)通过催化变革性研究扩大翻译老年科学的知识库;2)创造
一支拥有翻译老年学专业知识的多学科早期调查人员队伍;3)
作为来自其他OAIC和机构的调查人员的资源和合作伙伴;以及4)提供智力
领导,传播知识,并鼓励就与老年科学相关的翻译主题进行讨论。
SA OAIC通过领导和管理核心(LAC)实现这些目标
开展并赞助若干丰富和传播活动;试验性和探索性研究核心
(PESC)为严格设计的研究提供择优支持;研究教育部分
(REC),这扩大了一支急需的唯一合格的科学家队伍,他们在老化生物学和
翻译老年学;支持绒猴研究的临床前研究核心(RC1);
临床研究和药理学核心(RC2),提供全面的试验支持
招聘/保留、评估、药理学和数据管理;以及试验设计和综合
信息学核心(RC3),提供全面的研究设计、生物统计和信息学服务。
在自成立以来的约4年里,SA OAIC支持了46个PI,执行了变革性的翻译
以老年学为重点的研究基本上涵盖了老龄化的所有支柱/标志。例如,RC1正在进行
只有在非人类灵长类动物中关于mTOR抑制剂的已知寿命和健康跨度研究。执行了RC2和RC3
雷帕霉素对健康老年人的免疫和认知影响的首次试验,并进行了
第一个关于感光剂的人研究。OAIC资助了10名正在做出革命性发现的学者
(例如,首次证明细胞衰老是阿尔茨海默氏症病理的关键介质),并收到了很高的
NIA/FAAR(比森、艾琳·戴蒙德)和退伍军人管理局颁发的竞争性职业发展奖。
SA OAIC建立在UTHSCSA卓越且紧密集成的独特基础上
资源:内森休克中心、干预测试计划(ITP)现场、GRECC、T32培训
Grant on Geroscience,以及一个强大的Barshop研究所,将UTHSCSA的衰老研究统一起来。我们是唯一
具有所有这些协同组件的OAIC。此外,SA OAIC还收到了无与伦比的
机构承诺(约600,000美元/年),包括新的约1亿美元109,000平方米。英国《金融时报》建筑-特定于
Barshop Institute-将在一个位于中心的设施中容纳OAIC、休克中心和ITP。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sara Elyse Espinoza其他文献
Sara Elyse Espinoza的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sara Elyse Espinoza', 18)}}的其他基金
Geroscience Education and Training (GET) Network
老年科学教育和培训 (GET) 网络
- 批准号:
10472597 - 财政年份:2021
- 资助金额:
$ 126.69万 - 项目类别:
Geroscience Education and Training (GET) Network
老年科学教育和培训 (GET) 网络
- 批准号:
10270353 - 财政年份:2021
- 资助金额:
$ 126.69万 - 项目类别:
Does Metformin Modulate the Pillars of Aging in Older Adults?
二甲双胍能否调节老年人的衰老支柱?
- 批准号:
10087333 - 财政年份:2020
- 资助金额:
$ 126.69万 - 项目类别:
Does Metformin Modulate the Pillars of Aging in Older Adults?
二甲双胍能否调节老年人的衰老支柱?
- 批准号:
10661612 - 财政年份:2020
- 资助金额:
$ 126.69万 - 项目类别:
Does Metformin Modulate the Pillars of Aging in Older Adults?
二甲双胍能否调节老年人的衰老支柱?
- 批准号:
10432075 - 财政年份:2020
- 资助金额:
$ 126.69万 - 项目类别:
Does Metformin Modulate the Pillars of Aging in Older Adults?
二甲双胍能否调节老年人的衰老支柱?
- 批准号:
10266134 - 财政年份:2020
- 资助金额:
$ 126.69万 - 项目类别:
Metformin for Preventing Frailty in High Risk Older Adults
二甲双胍预防高危老年人的衰弱
- 批准号:
10165434 - 财政年份:2017
- 资助金额:
$ 126.69万 - 项目类别:
Metformin for Preventing Frailty in High Risk Older Adults
二甲双胍预防高危老年人的衰弱
- 批准号:
10439971 - 财政年份:2017
- 资助金额:
$ 126.69万 - 项目类别:
Metformin for Preventing Frailty in High Risk Older Adults
二甲双胍预防高危老年人的衰弱
- 批准号:
10598726 - 财政年份:2017
- 资助金额:
$ 126.69万 - 项目类别:
Metformin for Preventing Frailty in High Risk Older Adults
二甲双胍预防高危老年人的衰弱
- 批准号:
9239985 - 财政年份:2017
- 资助金额:
$ 126.69万 - 项目类别:














{{item.name}}会员




